Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies for cancer treatment. The company's core technology centers on autologous tumor-infiltrating lymphocytes (TILs), a personalized approach that utilizes a patient's own T cells to target and destroy cancer cells. Its flagship product, Amtagvi, is an FDA-approved TIL therapy indicated for adult patients with unresectable or metastatic melanoma. Iovance also offers Proleukin, an interleukin-2 therapy used in the treatment of metastatic melanoma and metastatic renal cell carcinoma. The company has a robust pipeline of investigational TIL therapies targeting a range of solid tumors, including melanoma, cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma, as well as therapies for hematologic malignancies like chronic lymphocytic leukemia and small lymphocytic lymphoma. Iovance's business model emphasizes a differentiated, personalized medicine approach to oncology, aiming to address unmet needs in difficult-to-treat cancers. The company has established strategic collaborations and licensing agreements with leading research institutions and pharmaceutical companies to advance its research and development efforts and expand its manufacturing capabilities. Headquartered in San Carlos, California, Iovance is committed to transforming cancer care through its pioneering cell therapy platform.